Targeted treatments, including mAbs, TKIs, ADCs, PI3K/Akt/mTOR pathway inhibitors, CDK4/6 inhibitors, PARP inhibitors, EGFR inhibitors and antiangiogenic agents have reshaped BC treatment paradigms. The gene discussed is AKT1; the disease is breast cancer.